Inventor · disambiguated record
Erica Ullman
Also filed as: ULLMAN ERICA
7 granted patents·15 pending applications·81 citations·filing 2016–2025
85Inventor score
Files withREGENERON PHARMA22
Top patents by PatentIndex Score
22 records- 0196US10358495B2Anti-LAG3 antibodies and uses thereofREGENERON PHARMA·Filed 2016·Granted Jul 23, 2019·47 cites·18 claims
- 0294US11548947B2Bispecific anti-PSMA X anti-CD28 antibodies and uses thereofREGENERON PHARMA·Filed 2019·Granted Jan 10, 2023·10 cites·17 claims
- 0393US11453721B2Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereofREGENERON PHARMA·Filed 2019·Granted Sep 27, 2022·10 cites·30 claims
- 0492US11905332B2Antigen-binding molecules that bind CD38 and/or CD28, and uses thereofREGENERON PHARMA·Filed 2021·Granted Feb 20, 2024·3 cites·43 claims
- 0591US11396544B2Bispecific anti-CD28 × anti-CD22 antibodies and uses thereofREGENERON PHARMA·Filed 2019·Granted Jul 26, 2022·8 cites·10 claims
- 0688US11692032B2Anti-LAG3 antibodies and uses thereofREGENERON PHARMA·Filed 2019·Granted Jul 4, 2023·3 cites·28 claims
- 0777US2024166740A1Anti-lag3 antibodies and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 0875US12441800B2Bispecific anti-PSMA x anti-CD28 antibodies and uses thereofREGENERON PHARMA·Filed 2022·Granted Oct 14, 2025·0 cites·14 claims
- 0971US2023174652A1Bispecific Anti-CD28 X Anti-CD22 Antibodies and Uses ThereofREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1070US2024067691A1Interferon receptor agonists and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1170US2024101633A1Interferon receptor agonists and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1270US2025043002A1BISPECIFIC PD-L1xCD28 ANTIBODIES AND METHODS OF USE THEREOFREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1368US2025223360A1Bispecific anti-cd28 x anti-cd22 antibodies and uses thereofREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1468US2023279113A1Bispecific Anti-MUC16 x Anti-CD28 Antibodies and Uses ThereofREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1567US2024277844A1Induced nk cells responsive to cd3/taa bispecific antibodiesREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1667US2025043017A1BISPECIFIC PD-L1x4-1BB ANTIBODIES AND METHODS OF USE THEREOFREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1766US2025179137A1Il18 receptor agonists and methods of use thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1865US2024376229A1Interferon receptor antagonists and uses thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1963US2023391844A1Interleukin-2 proproteins and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2062US2023416396A1Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2156US2025361309A1Tumor-targeted split il12 receptor agonistsREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2256US2023374160A1Combination of antibodies for treating cancer with reduced cytokine release syndromeREGENERON PHARMA·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Erica Ullman files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →